This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer (ANABRAQ)

This study has been terminated.
(Slow enrollment of patients.)
Sponsor:
Information provided by (Responsible Party):
Ipsen
ClinicalTrials.gov Identifier:
NCT01374087
First received: June 14, 2011
Last updated: December 28, 2016
Last verified: December 2016
  Purpose

The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy. Efficacy was to be assessed by biochemical failure-free survival (BFFS) curves from treatment initiation up to 5 years.

Secondary objectives included comparing the following: the differences in time to progression of subjects receiving brachytherapy + triptorelin 22.5 mg versus subjects receiving brachytherapy only, the BFFS percentages between both treatment groups at 5 years from treatment initiation, overall survival between both treatment groups, total testosterone changes (from baseline visit up to 12 months) and Prostate Specific Antigen (PSA) levels (from baseline visit up to 60 months of treatment) between both treatment groups, quality of life (QoL) modifications (Spanish version of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire) between the baseline score and the rest of measurements, and to compare safety between both treatment groups.


Condition Intervention Phase
Prostate Cancer Other: Brachytherapy + Triptorelin 22.5 mg Radiation: Brachytherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Proof-of-concept Multicentre, Prospective, Randomised, Open-label- Parallel-group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy Using Triptorelin 22.5 mg 6-month Formulation in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy

Resource links provided by NLM:


Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Biochemical Failure-free Survival (BFFS) [ Time Frame: 5 years ]

    BFFS was determined by a Prostate Specific Antigen (PSA) increase of 2 ng/mL or more in comparison with the pre-study nadir PSA (as per the Phoenix criteria) confirmed in the course of follow-up by a second value 3 weeks later or longer over the 5-year follow-up. Time to BFFS was defined from the "start date" to the first time when PSA increase of 2 mL was observed.

    As the study was prematurely terminated, no analyses were conducted. Data for BFFS are listed by subject for those individuals who reported biochemical failure. Time (months) to biochemical failure is relative to the date of brachytherapy.



Secondary Outcome Measures:
  • Time to Progression [ Time Frame: 5 years ]

    Time to progression (in months) was measured from the informed consent date to the date of first event occurrence. Progression was defined as either: death from all causes or disease progression (defined as PSA increased by 2 ng/mL as compared to the pre-trial nadir PSA, confirmed during follow-up by a second value after 3 or more weeks, or the diagnosis of a new clinical recurrence of their prostate cancer (metastasis, new injury, etc.)).

    As the study was prematurely terminated, no analyses were conducted. Data for time to progression are listed by subject for those individuals who reported progression.


  • BFFS Percentage 5 Years From Treatment Initiation [ Time Frame: 5 years ]

    A subject had a biochemical failure if there was an increase of PSA of 2 ng/mL or more in comparison with the pre-study nadir PSA confirmed in the course of follow-up by a second value after 3 or more weeks or with diagnosis of a new clinical recurrence of their prostate cancer over the 5-year follow-up.

    As the study was prematurely terminated, no data analyses were conducted. The study was terminated prior to completion of the 5-year follow-up.


  • Overall Survival [ Time Frame: 5 years ]

    Overall survival was defined as the time in months from diagnosis (biopsy date for local recurrence) to death due to any cause, the last visit or the loss to follow-up.

    No deaths were reported during the study. As the study was prematurely terminated, no data analyses were conducted. The study was terminated prior to completion of the 5-year follow-up.


  • Change in Total Testosterone Level [ Time Frame: 12 months ]

    Blood samples were drawn for serum testosterone at study initiation, and then at 3, 6 and 12 months.

    As the study was prematurely terminated, no data analyses were conducted. The study was terminated prior to completion of the 5-year follow-up.


  • Change in PSA Levels [ Time Frame: 5 years ]

    Blood samples were to be drawn for serum PSA at study initiation, and then at 3, 6, 12, 18, 24, 30, 36, 48 and 60 months.

    As the study was prematurely terminated, no data analyses were conducted. The study was terminated prior to completion of the 5-year follow-up.


  • Quality of Life (QoL) Modifications (Spanish Version of the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire) [ Time Frame: At every visit (except for Visit 2 (treatment administration visit)) ]

    EPIC assessed the disease-specific aspects of prostate cancer and its therapies and comprised four summary domains (Urinary, Bowel, Sexual and Hormonal). Factor analysis supported dividing the Urinary Domain Summary Score into two different Incontinence and Irritative/Obstructive subscales. In addition, each Domain Summary Score had measurable Function Subscale and Bother Subscale components. Response options for each EPIC item formed a Likert scale, and multi-item scale scores were transformed linearly to a 0-100 scale, with higher scores representing better Health-Related QoL.

    As the study was prematurely terminated, no data analyses were conducted. The study was terminated prior to completion of the 5-year follow-up.



Enrollment: 32
Study Start Date: November 2011
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Brachytherapy + Triptorelin 22.5 mg
Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
Other: Brachytherapy + Triptorelin 22.5 mg
Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
Active Comparator: Brachytherapy
Brachytherapy: Low or high dose rate.
Radiation: Brachytherapy
Brachytherapy: Low or high dose rate.

Detailed Description:

This was a proof-of-concept, prospective, parallel, multicentre, randomised and open-label trial, including a follow-up of all subjects conducted at 11 centres in Spain. Study visits included an inclusion visit (Visit 1), a treatment administration visit (Visit 2), and 9 follow-up visits (Visit 3 to Visit 11) from 3 to 60 months after study treatment administration. All of the procedures performed at these visits were in accordance with routine clinical practice. Subjects were randomised to any one of the two treatment arms (Group 1: brachytherapy only, or Group 2: brachytherapy + triptorelin 22.5 mg). Randomisation was stratified according to the brachytherapy dose rate (low or high dose rate).

Visit 1 included the collection of demographic data, a review of clinical details of prostate cancer and its treatment, blood sampling (for Prostate Specific Antigen (PSA), testosterone, and haematology and biochemistry parameters, as appropriate), administration of the QoL questionnaire and International Prostatic Symptom Score (IPSS), and treatment group allocation. Visit 2 included a review of the eligibility criteria, recording of concomitant medications and adverse events (AEs) and study drug administration. Visits 3 to 11 included recording of AEs and concomitant medications, blood sampling and administration of the QoL questionnaire and IPSS.

Following the selection visit (Visit 1), all subjects were scheduled to brachytherapy. Those subjects who were randomised to the concomitant hormone therapy group received a single dose of triptorelin 22.5 mg by intramuscular injection at Visit 2, 2 weeks following the selection visit (Visit 1), and preferably 2 months before receiving brachytherapy. One week before and two weeks after triptorelin administration, subjects were permitted to receive an anti-androgen to counteract a transient increase in testosterone levels.

The study was prematurely stopped due to the slow enrolment of subjects. Of the planned 86 evaluable subjects, 35 were screened, and 32 were randomised between 3 November 2011 and 26 May 2014. The slow inclusion of subjects was due to several factors, among which there were changes in clinical practice which caused such subjects to be offered alternative treatments to brachytherapy. Due to the small number of subjects, none of the planned efficacy analyses were performed. Instead, the data were analysed as follows:

  • Efficacy data and quality of life (QoL) outcomes were displayed only in listings.
  • Safety information was displayed using listings and summary tables.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A history of prostate cancer (T1-T2-T3 N0 M0), confirmed through histopathology and initially treated with radiotherapy.
  2. Age ≤ 75 years.
  3. Biochemical failure due to Phoenix criteria (nadir + 2) and local recurrence of the initial prostate cancer, confirmed by prostate biopsy, with neither regional involvement nor distant metastases.
  4. Late local recurrence of the initial prostate cancer. A recurrence is late when it appears after longer than 18 months post-radiotherapy.
  5. PSA < 10 ng/mL at the time of recurrence.
  6. The subject was required to be amenable to brachytherapy treatment.
  7. Adequate urinary function according to the questionnaire (IPSS ≤ 20 points).
  8. Suitable bone marrow function, determined by:

    • Haemoglobin > 10 g/dL.
    • Neutrophil count > 1.5 x 10^9/L.
    • Platelet count > 100 x 10^9/L.
  9. Suitable liver function determined by: serum bilirubin < 1.5 x Upper Normal Level (UNL), and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5xUNL.
  10. Suitable renal function determined by: serum creatinine < 1.5 x UNL, or creatinine clearance ≥ 60 mL/min.
  11. The subject was required to be ≥ 18 years old.
  12. The subject had to give his written informed consent (personally signed and dated) before starting with any study-related procedure.
  13. Life expectancy > 5 years.

Exclusion Criteria:

  1. Evidence of metastatic disease.
  2. Previous evidence of hormone-resistant cancer.
  3. Lack of availability for performing regular follow-up.
  4. Subjects who were receiving or had received either luteinizing hormone-releasing hormone (LH-RH) agonists, or antagonists, over the previous 12 months.
  5. Subjects who had been on treatment with other hormone therapies, including antagonists, megestrol acetate, finasteride, dutasteride, any herbaceous product known to reduce the PSA levels, or any systemic corticosteroid, over the previous 4 weeks.
  6. Subjects who had previously undergone a radiotherapy treatment that was completed within 18 months of inclusion.
  7. Subjects with pre-existing heart failure (New York Heart Association class III or IV), or with a myocardial infarction within 6 months of inclusion.
  8. Subjects with a significant co-existing disease or an active infection.
  9. Subjects who had been treated with investigational therapies within 4 weeks prior to the brachytherapy ± triptorelin treatment.
  10. Subjects with known hypersensitivity to triptorelin, LH-RH, other LH-RH-analogous agonists, or any excipients in triptorelin 22.5 mg.
  11. Subjects with a mental condition that prevented them from understanding the nature, the scope and the potential consequences of this study, and/or subjects who showed an uncooperative attitude.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01374087

Locations
Spain
Fundación IMOR
Barcelona, Spain
H. de la Santa Creu i Sant Pau
Barcelona, Spain
ICO Institut Català d'Oncologia-Hospitalet
Hospitalet de Llobregat, Spain
H. Ramón y Cajal
Madrid, Spain
H. Sanchinarro
Madrid, Spain
H. Carlos Haya
Málaga, Spain
Complejo Hospitalario de Navarra
Pamplona, Spain
Instituto Oncológico
San Sebastián, Spain
H. Universitario Marqués de Valdecilla
Santander, Spain
IVO Instituto Valenciano de Oncología
Valencia, Spain
H. Do Meixoeiro
Vigo, Spain
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Guillermo De la Cruz Sugrañas, M.D. Ipsen
  More Information

Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT01374087     History of Changes
Other Study ID Numbers: A-92-52014-177
2010-019158-41 ( EudraCT Number )
Study First Received: June 14, 2011
Results First Received: December 28, 2016
Last Updated: December 28, 2016

Keywords provided by Ipsen:
Recurrent Prostate Carcinoma
Brachytherapy
Triptorelin
Hormone Therapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Recurrence
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Disease Attributes
Pathologic Processes
Hormones
Triptorelin Pamoate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 21, 2017